RT Journal Article
SR Electronic
T1 Connecting omics signatures of diseases, drugs, and mechanisms of actions with iLINCS
JF bioRxiv
FD Cold Spring Harbor Laboratory
SP 826271
DO 10.1101/826271
A1 Marcin Pilarczyk
A1 Michal Kouril
A1 Behrouz Shamsaei
A1 Juozas Vasiliauskas
A1 Wen Niu
A1 Naim Mahi
A1 Lixia Zhang
A1 Nicholas Clark
A1 Yan Ren
A1 Shana White
A1 Rashid Karim
A1 Huan Xu
A1 Jacek Biesiada
A1 Mark F. Bennett
A1 Sarah Davidson
A1 John F Reichard
A1 Kurt Roberts
A1 Vasileios Stathias
A1 Amar Koleti
A1 Dusica Vidovic
A1 Daniel J.B. Clarke
A1 Stephan C. Schurer
A1 Avi Ma’ayan
A1 Jarek Meller
A1 Mario Medvedovic
YR 2020
UL http://biorxiv.org/content/early/2020/11/08/826271.abstract
AB There are only a few platforms that integrate multiple omics data types, bioinformatics tools, and interfaces for integrative analyses and visualization that do not require programming skills. Among these, iLINCS is unique in scope and versatility of the data provided and the analytics facilitated. iLINCS (http://ilincs.org) is an integrative web-based platform for analysis of omics data and signatures of cellular perturbations. The platform facilitates analysis of user-submitted omics signatures of diseases and cellular perturbations in the context of a large compendium of pre-computed signatures (>200,000), as well as mining and re-analysis of the large collection of omics datasets (>12,000), pre-computed signatures, and their connections. Analytics workflows driven by user-friendly interfaces enable users with only conceptual understanding of the analysis strategy to execute sophisticated analyses of omics signatures, such as systems biology analyses and interpretation of signatures, mechanism of action analysis, and signature-driven drug repositioning. In summary, iLINCS workflows integrate vast omics data resources and a range of analytics and interactive visualization tools into a comprehensive platform for analysis of omics signatures.Competing Interest StatementThe authors have declared no competing interest.